Attached files
| file | filename |
|---|---|
| EX-16.1 - China Polypeptide Group, Inc. | v173467_ex16-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of
1934
Date of Report (Date of Earliest Event
Reported): February 5, 2010
CHINA POLYPEPTIDE GROUP, INC.
(Exact Name of Registrant as Specified
in its Charter)
|
Delaware
|
333-151148
|
20-8731646
|
|
(State or other Jurisdiction of
Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer Identification
No.)
|
No. 11 Jiangda Road
Jianghan Economical Development Zone
430023 Wuhan, P.R.
China
|
(Address of Principal Executive
Offices)
|
Registrant’s telephone number, including area
code: (86) 2783518396
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation under any of the
following provisions ( see General Instruction A.2.
below):
|
o
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
o
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
|
|
o
|
Pre-commencement communications
pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 4.01. Changes in
Registrant’s Certifying
Accountant
On
February 5, 2010, China Polypeptide Group, Inc. (f/k/a Hamptons Extreme, Inc.)
(the “Company”)
dismissed Li & Company, PC (“Li &Co.”) as its
independent registered public accounting firm in connection with the Stock
Exchange Agreement (the
“Exchange
Agreement”)
completed on November 13, 2009, when the Company’s principal business
became that of Cantix International Ltd. (the
“Operating Company”). The decision to dismiss Li & Co. as the Company’s
independent auditor was approved by the Company’s Board of Directors. None of the reports of Li
&Co. on the Company’s financial statements for the past two fiscal years or
subsequent interim period contained an adverse opinion or a disclaimer of
opinion, or was qualified or modified as to uncertainty, audit scope or
accounting principles, except that the Li & Co.’s report on the Company’s
audited financial statements dated March 13, 2009 contained in its Form 10-K for
the fiscal year ended December 31, 2008 and 2007 included a going concern
qualification with respect to uncertainty as to the Company’s ability to
continue as a going concern.
During
the Company’s two most recent fiscal years and the subsequent interim period
through February 5, 2010, there were no disagreements with Li & Co. on any
matter of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure, which, if not resolved to Li &Co.’s
satisfaction, would have caused it to make reference to the subject matter of
the disagreement in connection with its report on the Company’s financial
statements and there were no "reportable event” as defined in
Item 304(a)(1)(v) of Regulation S-K.
The
Company has requested that Li &Co. furnish it with a letter addressed to the
Securities and Exchange Commission stating whether it agrees with the above
statements. A copy of such letter, dated February 8, 2010, is
attached to this Form 8-K as Exhibit 16.1 and is filed herewith.
Appointment
of New Auditor
On
February 5, 2010 and effective immediately, the Company, upon the approval of
the Board of Directors, engaged Bernstein & Pinchuk LLP (“B&P”), the
current auditor for the Company’s wholly owned subsidiary, as the Company’ new
independent registered public accounting firm for the fiscal year ending
September 30, 2010, and to perform procedures related to the financial
statements included in the Company’ annual report on Form 10-K and
quarterly reports on Form 10-Q, beginning with, and including, the year ending
September 30, 2010. The Company has not consulted with B&P during its fiscal
years ended December 31, 2008, prior fiscal year end, the period from March 19,
2007 (inception) through December 31, 2007 and the period from March 19, 2007
(inception) through December 31, 2008, and the interim period from December 31,
2008 through February 5, 2010, regarding either (i) the application of
accounting principles to a specified transaction, either completed or proposed;
or the type of audit opinion that might be rendered on the Company’s
consolidated financial statements, and neither a written report was provided to
the Company nor oral advice was provided that B&P concluded was an important
factor considered by the Company in reaching a decision as to the accounting,
auditing or financial reporting issue; or (ii) any matter that was either
the subject of disagreement (as defined in Item 304(a)(1)(iv) of Regulation
S-B and the related instructions) or a reportable event (within the meaning of
Item 304(a)(1)(v) of Regulation S-K).
|
Item
9.01.
|
Financial
Statement and Exhibits
|
|
(c
)
|
Exhibits
|
||
|
16.1
|
Letter
from Li & Company, PC to the Commission, dated February 8,
2010.
|
||
SIGNATURES
Pursuant to the requirements of
Section12 of the Securities Exchange Act of 1934, as amended the Registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
|
China Polypeptide Group,
Inc.
|
|||
|
Date: February 8, 2010
|
By:
|
/s/ Dongliang
Chen
|
|
|
Name: Dongliang Chen
Title: Chairman and Chief
Executive Officer
|
|||